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Background:  Highly  pathogenic  avian  inﬂuenza  A/H5N1  viruses  continue  to circulate  in birds  and  infect
humans  causing  serious  illness  and  death.
Methods: In this  randomized,  observer-blinded  study,  adults  ≥18  years  of  age  (n  = 841)  received  3.75 or
7.5 g hemagglutinin  antigen  (HA)  of an  AS03-adjuvanted  (AS03A or AS03B)  A/Indonesia/5/2005  H5N1
(subclade  2.1)  vaccine  (priming),  followed  by  the  same  HA dose  of  AS03-adjuvanted  A/turkey/Turkey/1/05
H5N1  (clade  2.2)  inﬂuenza  vaccine  as a  booster  6 or 18  months  after  priming;  an  unprimed  group  received
placebo  at  Day  0,  and  3.75  g HA of AS03A-adjuvanted  booster  vaccine  at 6  and  18  months.  Antibody
responses  were  assessed  by  hemagglutination-inhibition  assay  (HI).  Microneutralization  (MN)  antibody
and cellular  immunoassays  were  assessed  in  a  subset  of  participants.
Results:  Geometric  mean  titers  (GMTs)  and  seroconversion  rates  (SCRs)  were  higher  in primed  vs.
unprimed  subjects  against  the  booster  strain  10  days  following  booster  vaccination  at month  6  and
month  18.  After  the  booster  at 18 months,  the  lower  limit  of  the  97.5%  conﬁdence  interval  for  the  dif-
ference  in  SCR  and  GMT  ratios  between  primed  and  unprimed  subjects  was  >15% and  >2.0,  respectively,
fulﬁlling  the primary  endpoint  criteria  for superiority  against  the  booster  strain.  MN  and  cellular  immune
responses  corresponded  with  the  immunogenicity  seen  in  HI measures.
Conclusions:  Adults  primed  with  a dose-sparing  oil-in-water  adjuvanted  H5N1  subclade  vaccine  had  rapid
and durable  antibody  responses  to  a heterologous  subclade  boosting  vaccine  given 6 or 18  months  later.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Background
Following the emergence of highly pathogenic avian inﬂuenza
/H5N1 viruses in 1996, human illnesses occurred in 1997, result-
ng in six deaths among 18 affected persons [1]. H5N1 viruses
ontinue to circulate in poultry and other avian species, with
ntermittent human infection linked almost exclusively to animal
∗ Corresponding author. Tel.: +1 902 470 8141; fax: +1 902 470 7232.
E-mail addresses: jmlangle@dal.ca, joanne.langley@dal.ca (J.M. Langley).
ttp://dx.doi.org/10.1016/j.vaccine.2014.11.018
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
contact. Despite the rarity of human disease, the 59% (340/577)
mortality rate for the period 2003–2012 [2], and the theoretical
possibility that H5N1 could evolve to acquire efﬁcient human-to-
human transmissibility, justiﬁes its status as a concerning human
health threat. The recent report that H5N1 viruses can be altered in
the laboratory setting to enhance transmissibility in mammals has
only heightened awareness that pandemic preparedness for avian
inﬂuenza virus evolution is essential [3].
Proposed inﬂuenza pandemic preparedness vaccination strate-
gies include deploying a pre-existing subtype-speciﬁc vaccine stock
to provide some cross-protection against an emerging pandemic
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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train, or using a subtype-speciﬁc vaccine to prime a population
efore the pandemic followed by boosting with a strain-matched
accine during the pandemic [4]. The latter strategy requires that
he pre-pandemic vaccine primes the immune system against the
ventual drift variant pandemic strain virus.
Immunogenicity studies of H5 inﬂuenza vaccines have exam-
ned intrasubtypic heterologous immunity to drifted viruses of
ther H5N1 clades and subclades produced by priming strains, and
mmunity produced by heterologous boosting with drifted H5N1
trains 6 months–8 years after the priming series [5–12]. Although
ome of these studies involve small sample sizes, they provide
vidence that priming followed by heterologous boosting with a
rifted strain can induce cross-protective antibody responses, with
il-in-water adjuvanted vaccines producing the highest titers and
nadjuvanted vaccines being poor immunogens [13]. The dura-
ion of these cross-protective priming responses is incompletely
haracterized.
This study assessed the immunogenicity and safety of a heterol-
gous subclade H5N1 inﬂuenza vaccine given 6 or 18 months after
riming with a single, low-dose, oil-in-water adjuvanted primary
accination or placebo in adults.
. Methods
This was a randomized, observer-blind, placebo-controlled
tudy, conducted at 13 centers in the United States (US) and Canada
rom 11 July 2008 to 22 April 2010. Participants were allocated to
ne of seven study groups (Fig. 1) with varying antigen and adju-
ant doses and timings of booster vaccination (6 or 18 months).
he study protocol was approved by local or central ethical review
oards for each study center, and was conducted in accordance with
ood Clinical Practice, the Declaration of Helsinki, the US Code of
ederal Regulations for the Protection of Human Subjects, the Cana-
ian Tri-Council Policy Statement on Ethical Conduct for Research
nvolving Humans, and all relevant Canadian and US regulations.
he trial is registered at ClinicalTrials.gov (NCT00719043).
.1. ParticipantsAdults aged ≥18 years with stable health status in the month
rior to enrolment were eligible. Exclusionary criteria were pres-
nce of immune suppressive conditions (such as cancer, treatment
or cancer, and receipt of immunosuppressive therapy), allergy to
Fig. 1. Study  33 (2015) 559–567
vaccine components, pregnancy or lactation, conditions rendering
the subject unlikely to provide accurate safety reports, coagulopa-
thy, febrile illness, or previous receipt of H5N1 vaccine or recent
receipt of blood products. Participants who  took analgesics or
antipyretics for the purpose of prevention of vaccine reactogenicity
were also excluded.
2.2. Vaccines
The study vaccines contained monovalent split virus
A/Indonesia/5/2005 (H5N1) or A/turkey/Turkey/1/2005 (H5N1)
antigen. Each dose of vaccine contained either 3.75 g HA or
7.5 g HA with one of two  adjuvant doses: AS03A—Adjuvant
System 03 (containing -tocopherol [11.86 mg]  and squalene in
an oil in water emulsion), or AS03B (5.93 mg  -tocopherol). When
mixed with the adjuvant for use, each 0.5 mL  of vaccine contained
5 g/mL of thimerosal. Inﬂuenza virus strains were obtained from
the Centers for Disease Control and Prevention and manufactured
by GlaxoSmithKline (GSK) Vaccines (Ste-Foy, Quebec, Canada).
On the day of vaccine administration, the vaccine antigen and
adjuvant were mixed 1:1 by study personnel in a separate area
to preserve observer-blind status; these personnel took no other
part in study conduct. Wrap-around labels were used to obscure
vial contents from study subjects. The placebo vaccine was sterile
phosphate buffered saline. The vaccine antigen combined with the
adjuvant appeared as a white liquid. Vaccines were administered
into the deltoid region of the arm by the intramuscular route.
2.3. Study procedures
Participants were randomly allocated to one of seven study
groups in a ratio of 1:1:1:1:1:1:1 (Fig. 1) using a minimization
procedure that accounted for center and age (18–40, 41–64, and
≥ 65 years) using an internet-based central randomization sys-
tem [14]. Six groups (A–F) received a single priming dose of
A/Indonesia/5/2005 (H5N1) vaccine at Day 0; and one group (G)
received placebo at Day 0. Six and 18 months after the primary
dose, subjects received the H5N1 booster vaccine from a different
subclade (A/turkey/Turkey/1/2005) or placebo.
All participants were to receive a total of three intramuscular
injections including both study vaccine (two doses) and placebo
design.
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one dose), on Days 0, 182 (6 months) and 549 (18 months; obser-
ations continued until Day 909 [30 months]; Fig. 1).
.4. Immunogenicity outcomes
Blood was collected for serological assessment of immuno-
enicity on Days 0, 10, 42, 182, 192, 224, 549, 559, 591, and
29. The primary immunogenicity analyses were based on anti-
ody titers 10 days after each vaccination (Days 10, 192, and
59). Immune response was measured using standard HI assay
ethods modiﬁed to utilize an equine erythrocyte suspension
nstead of an avian erythrocyte suspension. HI titers were assessed
gainst the inﬂuenza virus antigens, A/turkey/Turkey/1/2005
H5N1) and A/Indonesia/5/2005 (H5N1). Sera were tested in
uplicate by blinded personnel at GSK Vaccines (Dresden,
ermany).
The HI endpoints were: seroconversion rate (SCR) deﬁned as the
ercentage of participants who had pre- and post-vaccination titers
f <1:10 and ≥1:40, respectively, or showed a signiﬁcant increase in
ntibody titer (a pre-vaccination titer of ≥1:10 and ≥4-fold increase
n post-vaccination titer); and seroprotection rate (SPR) deﬁned
s the percentage of participants with titers of ≥1:40. The Food
nd Drug Administration (FDA) Center for Biologics Evaluation and
esearch (CBER) accelerated approval licensure criteria require that
he lower limits of the 95% conﬁdence intervals (CI) for SCR are
40% and ≥30% and for SPR are ≥70% and ≥60% for participants
ged 18–64 years and ≥65 years, respectively.
For the analysis of European Medicine Agency’s (EMA) Commit-
ee for Medicinal Products for Human Use (CHMP) criteria, point
stimates of SCR needed to be >40% and >30% and SPR needed to
e >70% and >60% for subjects aged 18–60 years and ≥61 years,
espectively [15]. The geometric mean fold rise (GMFR) was  deﬁned
s the geometric mean of the within-subject ratios of pre- and
ost-vaccination reciprocal HI titers. GMFRs of >2.5 and >2.0 were
equired in the 18–60 and ≥61 years age groups, respectively, to
ulﬁl the CHMP licensure criterion [15].
Microneutralization (MN) assays were performed for a subset
f subjects selected at the time of randomization, in triplicate,
n thawed frozen serum samples against A/turkey/Turkey/1/2005
H5N1), A/Indonesia/5/2005 (H5N1), and the Clade 1 virus
/Vietnam/1194/2004 (H5N1). MN  testing was done according to
he World Health Organization (WHO) protocol [16] with the fol-
owing modiﬁcations: the incubation period was extended to 7 days
nd the ELISA detection of non-neutralized wells was  replaced by
A detection in the supernatant. The MN vaccine response rate
VRR) was deﬁned as the incidence rate of vaccinees with an at
east fourfold increase in post-vaccination reciprocal titer relative
o Day 0. Participants with an antibody titer of <1:28 were consid-
red seronegative, and the reciprocal titer value assigned to a MN
esults below cut-off was one-half of the cut-off value, or 14. If the
aseline titer was below cut-off and the post-vaccination recipro-
al titer was ≥56, the participant was deemed to have had a MN
accine response [17,18].
Cellular immunoassays were performed on a subset of partic-
pants using cryopreserved peripheral blood mononuclear cells
PBMCs) [19]. In brief, PBMCs and a stimulating antigen or pep-
ide pool were incubated for 2 h, and then incubated with the
ytokine secretion inhibitor Brefeldin A overnight. Cells were
arvested, stained for CD4 and CD8 surface markers, ﬁxed, per-
eabilized, and stained with anti-cytokine-speciﬁc antibodies.
fter washing, cytoﬂuorometry was performed to determine the
requency of CD4+ and CD8+ T cells responding to antigen and
xpressing at least two  of four markers: interferon gamma  (IFN),
nterleukin 2 (IL-2), tumor necrosis factor alpha (TNF), and
D40-L. 33 (2015) 559–567 561
2.5. Reactogenicity and safety outcomes
Participants were observed for 30 min following each vaccina-
tion. A diary card was  provided to record injection-site and systemic
(general) solicited adverse events (AE) occurring on the day of vac-
cination and for the subsequent 6 days, including oral temperature
and maximum severity of each symptom per 24 h period using a
standard scale. Targeted examination for axillary and/or supracla-
vicular lymph node enlargement and tenderness were conducted
using standard grading deﬁnitions by study staff at nine time points
through Day 909.
Solicited injection site AEs were presumed to be vaccine-related
and investigators provided causality assessment for solicited sys-
temic AEs. All unsolicited AEs were collected for 42 days following
each dose. AEs recorded by participants were collected during study
visits and by telephone contact on three occasions. Serious AEs
(SAEs) and AEs requiring any unscheduled encounter with a med-
ical caregiver (MAEs) and potentially immune-mediated disorders
(pIMDs) were collected during the entire study period (Day 0–Day
909).
2.6. Statistical analyses
Immunogenicity analyses were performed on the According-to-
Protocol (ATP) immunogenicity cohort which included participants
with complete data for the primary immunogenicity endpoints, and
who did not meet elimination criteria.
Safety analyses were performed on the total vaccinated cohort
(TVC) which included those who received at least one dose of
vaccine or placebo and for whom any post-vaccination data were
available.
The target sample size of 840 was calculated to support the pri-
mary immunogenicity objective of determining whether a single
dose of AS03-adjuvanted H5N1 vaccine was  more immunogenic
when given to participants who had been primed with a heterolo-
gous H5N1 vaccine 18 months previously than in participants who
had not received priming vaccination. The primary comparisons
for the Month 18 booster were groups C vs.  G (booster effect) and
E vs.  G (booster with higher antigen content). If one of these com-
parisons was  signiﬁcant, F vs.  G (booster with lower adjuvant and
higher antigen content) and D vs.  G (booster with lower antigen
content) were compared.
Superiority of single-dose booster vaccination over single-dose
primary vaccination 10 days after booster vaccination was consid-
ered to be established if the lower limit of the 97.5% CI for the
difference in SCR (A–F vs.  G ([H5N1-naïve group]) was  >15%, and
the lower limit of the 97.5% CI for the adjusted GMT  ratio (A–F vs.
G) was  >2.0. GMTs were adjusted for age and pre-vaccination anti-
body titer; an ANCOVA (Analyse of Covariance) model was used to
obtain the adjusted GMT  ratios with the CI.
Cellular immune responses were performed as previously
described [20].
Analyses were performed using Statistical Analysis System (SAS)
version 9.1 (SAS, Cary, NC) except for CI proportions within a group
which were calculated using Proc StatXact 5.0 (Cytel, Cambridge,
MA).
3. Results
3.1. Demographics and participant dispositionAll 841 enrolled adults were vaccinated (TVC) and 731 com-
prised the ATP immunogenicity cohort. Demographic and clinical
characteristics of the TVC cohort are shown in Supplemental Table
1. Subject disposition, reasons for withdrawal and ﬂow through Day
562 J.M. Langley et al. / Vaccine 33 (2015) 559–567
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09 are seen in Fig. 2. At Day 729 (immunogenicity analysis), 75% of
he ATP immunogenicity cohort remained; there was no difference
n subject retention between study groups.
.2. Immunogenicity
Compared with the placebo-primed group, the groups primed
ith A/Indonesia/5/2005 inﬂuenza vaccine and boosted with (het-
rologous) A/turkey/Turkey/1/2005 vaccine at Month 6 or 18 had
uperior A/turkey/Turkey/1/2005 antibody responses relative to
nprimed subjects, as measured by SCRs and adjusted GMT  ratios
0 days after the booster dose (Table 1 and Fig. 3). The lower limit
f the 97.5% CI for the difference in SCRs and adjusted GMT  ratios
etween primed (A–F) and H5N1-naïve subjects (G) was >15% and
2.0, respectively (Table 2).
Superiority of the A/turkey/Turkey/1/2005 antibody responses
n the primed compared with the unprimed participants was seen
n all study groups, whether boosting occurred at Month 6 or Month
8 after priming (Groups A vs. D or B vs. F), whether priming and
ooster doses had low or high antigen content (Groups C vs. E or
 vs. F), or whether priming and booster doses were adjuvanted
ith AS03A or AS03B (Groups C vs. D or E vs. F). The duration of
eterologous booster immune responses over time are shown in
able 3 and Fig. 3.
The VRR for neutralizing antibodies against A/Indonesia at 10
nd 42 days following receipt of A/Indonesia vaccine and A/Turkey
ooster and is shown in Supplemental Figs. 1 and 2. Neutralizing
MTs to the A/turkey booster dose virus were higher in participants
ho had been primed with A/Indonesia compared to H5N1 naïve
articipants.t ﬂow.
CD4+ T cell responses are shown in Supplemental Fig. 4. Cor-
responding with HI results, higher responses were observed for
primed rather than unprimed participants. No induction of a CD8+
T cell response was  observed.
3.3. Reactogenicity and safety
The most commonly reported injection-site symptom was  pain
(Table 3), which was reported by 68–78% of vaccine recipients
compared with 8% of placebo recipients after the ﬁrst dose of
vaccine or placebo. The majority of solicited systemic AEs were
considered related to vaccine in all study groups; all solicited gen-
eral AEs are presented in Table 3. Grade 3 (severe) symptoms
were reported by up to 5.8% of subjects given a vaccine at any of
the three vaccination time points. The most frequently reported
solicited systemic AEs were muscle aches and fatigue, reported by
17.3–35.1% of those receiving AS03-adjuvanted vaccine, compared
with 4.5–18.4% of those receiving placebo. The unsolicited adverse
event proﬁles including MAE  and SAE events were similar across
all treatment groups (data not shown). One SAE was  considered to
be vaccine-related, angina pectoris, occurring 10 days after Day 0
H5N1 vaccination in a participant with diabetes who was receiving
varenicline for smoking cessation.
4. Discussion
One challenging aspect of planning for pandemic vaccine pro-
grams is the inability, given currently approved vaccines, to rapidly
manufacture large quantities of pandemic-strain speciﬁc antigen.
Infection prevention strategies while awaiting pandemic vaccine
availability include antiviral prophylaxis, use of infection control
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Table  1
SCRs and adjusted GMT  ratios against A/turkey/Turkey/1/2005 (H5N1) in primed vs. unprimed subjects at 10 days following the ﬁrst A/turkey/Turkey/1/2005 vaccine
administration (According to Protocol-Immunogenicity Cohort).
3.75 Indo-
AS03B/3.75
Turkey-
AS03B/PLA
(n = 105)
7.5 Indo-
AS03B/7.5
Turkey-
AS03B/PLA
(n = 102)
3.75 Indo-
AS03A/PLA/3.75
Turkey-AS03A
(n = 104)
3.75 Indo-
AS03B/PLA/3.75
Turkey-AS03B
(n = 106)
7.5 Indo-
AS03A/PLA/7.5
Turkey-AS03A
(n = 107)
7.5 Indo-
AS03B/PLA/7.5
Turkey-AS03B
(n = 98)
PLA/3.75
Turkey-
AS03A/3.75
Turkey-AS03A
(n = 109)
Group  name A B C D E F G
Status
Primed/unprimed
(Booster dose)
Primed
(6 months)
Primed
(6 months)
Primed
(18 months)
Primed
(18 months)
Primed
(18 months)
Primed
(18 months)
Unprimed
SCR
na/N 73/94 81/86 71/83 81/87 73/80 65/72 44/99
SCR  rate, % 77.7 94.2 85.5 93.1 91.3 90.3 44.4
Difference in SCR, %
(97.5% CI)
33.22
(17.75, 47.11)b
49.74
(38.17, 60.10)b
41.10
(25.97, 54.24)
48.66
(35.09, 60.56)
46.81
(32.54, 59.10)
45.83
(30.94, 58.42)
–
Adjusted GMT  ratios
nc 94 86 83 87 80 72 99
Adjusted GMT  ratio
(97.5% CI)
6.88
(4.66, 10.16)b
9.28
(6.44, 13.38)b
8.40
(5.31, 13.29)
6.50
(4.18, 10.10)
11.53
(7.30, 18.22)
8.61
(5.37, 13.81)
–
a Number of subjects with titer within the speciﬁed range.
b 95% conﬁdence intervals are presented for the groups primed at 6 months.
c Number of subjects with both pre- and post-vaccination results available.
Adjusted GMT  ratio, geometric mean antibody titer ratio adjusted for age and baseline titer; CI, conﬁdence interval; Indo, A/Indonesia/5/05 (H5N1) vaccine; SCR, seroconversion
rate  (percentage of subjects who had pre- and post-vaccination titers of <1:10 and ≥1:40, respectively, or who had a pre-vaccination titer of ≥1:10 and a ≥4-fold increase in
post-vaccination titer); Turkey, A/turkey/Turkey/1/2005 (H5N1) vaccine; PLA, placebo (phosphate buffered saline).
N,  number of subjects with available results.
Primed/unprimed status: subjects were primed with heterologous A/Indonesia5/0205 (H5N1) 6 or 18 months prior to boosting with A/turkey/Turkey/1/2005; unprimed
subjects received placebo at Day 0.
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croup names indicate the sequence in which vaccine or placebo was administered 
accines were delivered as 3.75 g or 7.5 g hemagglutinin antigen and formulated
AS03A), or 5.93 mg  tocopherol (AS03B).
easures, or provision of a vaccine containing homo-subtypic, but
mperfectly matched, antigen. This last strategy could be imple-
ented as a ﬁrst measure in the face of an immediate pandemic
hreat, or implemented pre-emptively by providing a priming dose
o high-risk populations in advance of a pandemic. For such a
trategy to be advantageous, the vaccine would have to provide
ome cross-protection to a novel pandemic strain should expo-
ure occur before the booster pandemic strain vaccine is given.
xisting adjuvanted A/H5N1 vaccines that produce relatively broad
ross-reactive serologic responses can potentially meet this need
nd are cited below. In addition, a single booster vaccination with
he pandemic strain vaccines, when it becomes available, should
rovide better protection to primed individuals than a single-dose
train-matched vaccine administered to an unprimed population.
Like other inﬂuenza viruses, H5N1 strains have gradually drifted
enetically over time and have evolved into multiple geneti-
ally similar groups, or clades and subclades. Clinical trials of
Fig. 3. Geometric mean antibody titers at all time pointsys 0, 182, and 549.
 tocopherol-based-oil-in-water emulsion adjuvant containing 11.86 mg tocopherol
diverse types of H5N1 vaccines have demonstrated that cross-clade
antibody titers are present following priming immunization. An oil-
in-water adjuvanted H5N1 vaccine candidate based on inﬂuenza
A/Duck/Singapore/97 (H5N3) showed robust cross-immunity to
A/Hong Kong/489/97 (H5N1), suggesting drift-variant immunity
[21]. Subsequent studies of various vaccines based on the clade 1
A/Vietnam virus [11,22–28], and the clade 2.1 A/Indonesia strain
[24,29], have shown signiﬁcant titers of cross-protective antibodies
against these clades, as well as subclades 2.2 (Turkey), 2.3 (Anhui),
and against the original clade 3 virus (Hong Kong/156/1997) [23].
Fewer studies have evaluated the immunogenicity of a het-
erologous drift-variant H5N1 vaccine given 6 months or more
after the priming vaccine(s) [5,7,9,12]. Of these, only two  have
assessed the immunogenicity of a single priming dose. In a study
of 37 subjects primed with a baculovirus-expressed recombinant
hemagglutinin A/HK/156/1997 vaccine administered with MF59
adjuvant 8 years previously, a single 90 g booster dose of a
 (According-To-Protocol–Immunogenicity cohort).
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Table 2
HI SCRs, GMTs, and antibody titers ≥1:40 against A/turkey/Turkey/1/2005 in primed and unprimed subjects throughout the study period (According to Protocol-
Immunogenicity Cohort).
3.75 Indo-
AS03B/3.75
Turkey-
AS03B/PLA
(n = 105)
7.5 Indo-
AS03B/7.5
Turkey-
AS03B/PLA
(n = 102)
3.75 Indo-
AS03A/PLA/3.75-
Turkey AS03A
(n = 104)
3.75 Indo-
AS03B/PLA/3.75
Turkey-AS03B
(n = 106)
7.5 Indo-
AS03A/PLA/7.5
Turkey-AS03A
(n = 107)
7.5 Indo-
AS03B/PLA/7.5
Turkey-AS03B
(n = 98)
PLA/3.75
Turkey-
AS03A/3.75
Turkey-AS03A
(n = 109)
Group name A B C D E F G
Status
Primed/unprimed
(Booster dose)
Primed
(6 months)
Primed
(6 months)
Primed
(18 months)
Primed
(18 months)
Primed
(18 months)
Primed
(18 months)
Unprimed
SCR  at 42 days following the ﬁrst dose of A/turkey/Turkey/1/2005 vaccine given at Day 182 or Day 549
na/N 64/89 75/86 69/82 80/88 70/80 61/71 42/98
SCR,  %
(95% CI)
71.9
(61.4, 80.9)
87.2
(78.3, 93.4)
84.1
(74.4, 91.3)
90.9
(82.9, 96.0)
87.5
(78.2, 93.8)
85.9
(75.6, 93.0)
42.9
(32.9, 53.3)
GMTs  for antibodies against A/turkey/Turkey/1/2005
N
GMT  (95% CI)
Day 0 (Dose 1) 95
9.2 (7.4, 11.4)
92
6.6 (5.7, 7.7)
90
8.0 (6.6, 9.8)
98
7.0 (6.0, 8.2)
99
6.6 (5.7, 7.6)
89
6.9 (5.9, 8.0)
100
8.2 (6.8, 9.9)
Day  10 50
29.3
(20.6, 41.6)
49
21.3
(14.9, 30.5)
44
25.5
(16.4, 39.5)
51
14.8
(10.8, 20.5)
44
24.7
(16.8, 36.4)
46
20.9
(14.2, 30.9)
46
8.2
(6.4, 10.6)
Day  42 50
28.5
(21.3, 38.1)
48
20.0
(14.6, 27.4)
42
27.6
(18.8, 40.4)
51
15.1
(11.2, 20.5)
43
24.3
(16.2, 36.3)
47
18.3
(13.2, 25.4)
–
Day  182 (Dose 2) 95
17.6
(13.1, 23.6)
92
12.2
(9.7, 15.4)
90
13.5
(10.3, 17.8)
98
10.8
(8.4, 13.8)
99
12.8
(10.0, 16.4)
89
13.7
(10.6, 17.7)
100
10.8
(8.4, 13.9)
Day  192 94
308.4
(231.1, 411.5)
86
374.4
(297.9, 470.5)
– – – – 99
43.5
(32.6, 58.0)
Day  224 89
194.5
(144.6, 261.6)
86
217.3
(172.4, 274.0)
– – – – 98
44.3
(32.6, 60.3)
Day  549 (Dose 3) 84
32.7
(24.4, 43.6)
81
28.7
(22.6, 36.5)
83
11.1
(8.8, 14.1)
88
8.3
(7.0, 9.7)
81
9.2
(7.6, 11.2)
72
11.4
(9.1, 14.4)
82
15.8
(12.2, 20.4)
Day  559 – – 83
356.7
(265.9, 478.5)
87
266.4
(202.2, 351.2)
80
446.6
(336.0, 593.7)
72
343.9
(254.2, 465.3)
81
311.8
(228.4, 425.7)
Day  591 46
45.1
(30.8, 66.0)
43
26.1
(19.1, 35.5)
82
300.3
(225.6, 399.7)
88
241.1
(181.2, 320.6)
80
326.9
(241.6, 442.2)
71
254.4
(188.5, 343.3)
81
237.1
(173.6, 323.7)
Day  729 78
41.8
(32.1, 54.4)
78
31.2
(24.8, 39.2)
81
119.2
(95.3, 149.0)
83
96.6
(75.1, 124.2)
79
134.8
(106.4, 170.9)
70
105.6
(84.1, 132.6)
80
98.1
(76.4, 125.9)
Proportion of subjects with antibody titers ≥1:40 against A/turkey/Turkey/1/05
nb/N
% (95% CI)
Day 0 (Dose 1) 16/95
16.8
(9.9, 25.9)
7/92
7.6
(3.1, 15.1)
11/90
12.2
(6.3, 20.8)
8/98
8.2
(3.6, 15.5)
8/99
8.1
(3.6, 15.3)
6/89
6.7
(2.5, 14.1)
9/100
9.0
(4.2, 16.4)
Day  10 26/50
52.0
(37.4, 66.3)
23/49
46.9
(32.5, 61.7)
18/44
40.9
(26.3, 56.8)
16/51
31.4
(19.1, 45.9)
22/44
50.0
(34.6, 65.4)
21/46
45.7
(30.9, 61.0)
6/46
13.0
(4.9, 26.3)
Day  42 26/50
52.0
(37.4, 66.3)
17/48
35.4
(22.2, 50.5)
22/42
52.4
(36.4, 68.0)
14/51
27.5
(15.9, 41.7)
21/43
48.8
(33.3, 64.5)
18/47
38.3
(24.5, 53.6)
–
Day  182 (Dose 2) 30/95
31.6
(22.4, 41.9)
25/92
27.2
(18.4, 37.4)
25/90
27.8
(18.9, 38.2)
20/98
20.4
(12.9, 29.7)
28/99
28.3
(19.7, 38.2)
31/89
34.8
(25.0, 45.7)
24/100
24.0
(16.0, 33.6)
Day  192 89/94
94.7
(88.0, 98.3)
85/86
98.8
(93.7, 100.0)
– – – 64/99
64.6
(54.4, 74.0)
Day  224 82/89
92.1
(84.5, 96.8)
82/86
95.3
(88.5, 98.7)
– – – 60/98
61.2
(50.8, 70.9)
Day  549 (Dose 3) 42/84
50.0
(38.9, 61.1)
40/81
49.4
(38.1, 60.7)
15/83
18.1
(10.5, 28.0)
8/88
9.1
(4.0, 17.1)
10/81
12.3
(6.1, 21.5)
13/72
18.1
(10.0, 28.9)
22/82
26.8
(17.6, 37.8)
Day  559 79/83
95.2
(88.1, 98.7)
83/87
95.4
(88.6, 98.7)
77/80
96.3
(89.4, 99.2)
69/72
95.8
(88.3, 99.1)
77/81
95.1
(87.8, 98.6)
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Table  2 (Continued)
3.75 Indo-
AS03B/3.75
Turkey-
AS03B/PLA
(n = 105)
7.5 Indo-
AS03B/7.5
Turkey-
AS03B/PLA
(n = 102)
3.75 Indo-
AS03A/PLA/3.75-
Turkey AS03A
(n = 104)
3.75 Indo-
AS03B/PLA/3.75
Turkey-AS03B
(n = 106)
7.5 Indo-
AS03A/PLA/7.5
Turkey-AS03A
(n = 107)
7.5 Indo-
AS03B/PLA/7.5
Turkey-AS03B
(n = 98)
PLA/3.75
Turkey-
AS03A/3.75
Turkey-AS03A
(n = 109)
Day 591 27/46
58.7
(43.2, 73.0)
19/43
44.2
(29.1, 60.1)
77/82
93.9
(86.3, 98.0)
83/88
94.3
(87.2, 98.1)
75/80
93.8
(86.0, 97.9)
67/71
94.4
(86.2, 98.4)
74/78
91.4
(83.0, 96.5)
Day  729 47/78
60.3
(48.5, 71.2)
49/78
62.8
(51.1, 73.5)
75/81
92.6
(84.6, 97.2)
73/83
88.0
(79.0, 94.1)
71/79
89.9
(81.0, 95.5)
66/70
94.3
(86.0, 98.4)
70/80
87.5
(78.2, 93.8)
a Number of subjects with both pre- and post-vaccination results available.
b Number of subjects with antibody titer ≥1:40.
CI, conﬁdence interval; Indo, A/Indonesia/5/2005 (H5N1) vaccine; HI, hemagglutination-inhibition; Turkey, A/turkey/Turkey/1/2005 (H5N1) vaccine; GMT: geometric mean
titers;  PLA: placebo; SCR, seroconversion rate (percentage of subjects who had pre- and post-vaccination titers of <1:10 and ≥1:40, respectively, or who  had a pre-vaccination
titer  of ≥1:10 and a ≥4-fold increase in post-vaccination titer).
N,  number of subjects with available results.
G on Da
V  with a
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(roup names indicate the sequence in which vaccine or placebo was administered 
accines were delivered as 3.75 g or 7.5 g hemagglutinin antigen and formulated
AS03A), or 5.93 mg  tocopherol (AS03B).
ubvirion A/Vietnam/1194/2004 vaccine resulted in a GMT  of 64.0
ith 64% of vaccinees having a HI titer of ≥1:40 [7]. An opentudy of 512 subjects primed with AS03-adjuvanted vaccine with
.75 g A/Vietnam/1194/2004 and boosted 6 months later with the
ame vaccine or AS03-adjuvanted A/Indonesia/05/2005 resulted in
ver 90% seroprotection against either strain in the group receiving
able 3
olicited local (injection site) and general symptoms (overall by subject) within 7 days po
Event
n (%)
[95% CI]
3.75 Indo-
AS03B/3.75
Turkey-
AS03B/PLA
(n = 120)
7.5 Indo-
AS03B/7.5
Turkey-
AS03B/PLA
(n = 121)
3.75 Indo-
AS03A/PLA/3.75
Turkey-AS03A
(n = 119)
3.75 
AS03
Turk
(n = 1
A B C D 
Local (injection site) symptoms
Pain (all) 98 (81.7)
[73.6, 88.1]
100 (82.6)
[74.7, 88.9]
101 (84.9)
[77.2, 90.8]
93 (7
[69.6
Pain  (grade 3)
(at rest)
2 (1.7)
[0.2, 5.9]
7 (5.8)
[2.4, 11.6]
5 (4.2)
[1.4,9.5]
4 (3.4
[0.9, 8
Redness (all) 8 (6.7)
[2.9, 12.7]
4 (3.3)
[0.9, 8.2]
12 (10.1)
[5.3, 17.0]
9 (7.6
[3.5, 
Redness (grade 3)
(>100 mm)
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.0]
1 (0.8)
[0.0, 4.6]
0 (0.0
[0.0, 3
Swelling (all) 6 (5.0)
[1.9, 10.6]
7 (5.8)
[2.4, 11.6]
15 (12.6)
[7.2, 19.9]
4 (3.4
[0.9, 8
Swelling (grade 3)
(>100 mm)
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.1]
0 (0.0
[0.0, 3
General symptoms
Fatigue 45 (37.5)
[28.8, 46.8]
50 (41.3)
[32.4, 50.6]
47 (39.5)
[30.7, 48.9]
44 (3
[28.3
Headache 44 (36.7)
[28.1, 45.9]
50 (41.3)
[32.4, 50.6]
42 (35.3)
[26.8, 44.6]
44 (3
[28.3
Joint  pain at other
location
33 (27.5)
[19.7, 36.4]
37 (30.6)
[22.5, 39.6]
36 (30.3)
[22.2, 39.3]
26 (2
[14.8
Muscle  aches 54 (45.0)
[35.9, 54.3]
52 (43.0)
[34.0, 52.3]
59 (49.6)
[40.3, 58.9]
49 (4
[32.2
Shivering 12 (10.0)
[5.3, 16.8]
18 (14.9)
[9.1, 22.5]
16 (13.4)
[7.9, 20.9]
8 (6.7
[2.9, 
Sweating 15 (12.5)
[7.2, 19.8]
20 (16.5)
[10.4, 24.4]
15 (12.6)
[7.2, 19.9]
11 (9
[4.7, 
Fever
(oral  temperature
>38 ◦C)
2 (1.7)
[0.2, 5.9]
5 (4.1)
[1.4, 9.4]
6 (5.0)
[1.9, 10.7]
3 (2.5
[0.5, 7
LA:placebo, n: number
ndo, A/Indonesia/5/2005 (H5N1) vaccine; Turkey, A/turkey/Turkey/1/2005 (H5N1) vaccin
roup names indicate the sequence in which vaccine or placebo was  administered on Da
accines were delivered as 3.75 g or 7.5 g hemagglutinin antigen and formulated with a
AS03A), or 5.93 mg  tocopherol (AS03B).
accines were delivered as 3.75 g or 7.5 g hemagglutinin antigen and formulated with a
AS03A), or 5.93 mg  tocopherol (AS03B).ys 0, 182, and 549.
 tocopherol-based-oil-in-water emulsion adjuvant containing 11.86 mg tocopherol
the drift-variant booster [30]. Studies of the effect of drift-variant
boosting after a single priming dose have followed the duration
of responses from 21 to 56 days, with two studies assessing the
duration of titers to 6 months [5,30] and one study assessing
the duration of titers to 48 months in recipients of two  priming
doses[31].
st-vaccination in each treatment group (Total Vaccinated Cohort).
Indo-
B/PLA/3.75
ey-AS03B
19)
7.5 Indo-
AS03A/PLA/7.5
Turkey-AS03A
(n = 122)
7.5 Indo-
AS03B/PLA/7.5
Turkey-AS03B
(n = 120)
PLA/3.75
Turkey-
AS03A/3.75
Turkey-AS03A
(n = 120)
All
(n = 841)
E F G
8.2)
, 85.2]
102 (83.6)
[75.8, 89.7]
90 (75.0)
[66.3, 82.5]
95 (79.2)
[70.8, 86.0]
679 (80.7)
[77.9, 83.4]
)
.4]
6 (4.9)
[1.8, 10.4]
3 (2.5)
[0.5, 7.1]
5 (4.2)
[1.4, 9.5]
32 (3.8)
[2.6, 5.3]
)
13.9]
14 (11.5)
[6.4, 18.5]
4 (3.3)
[0.9, 8.3]
8 (6.7)
[2.9, 12.7]
59 (7.0)
[5.4, 9.0]
)
.1]
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.0]
1 (0.1)
[0.0, 0.7]
)
.4]
16 (13.1)
[7.7, 20.4]
9 (7.5)
[3.5, 13.8]
11 (9.2)
[4.7, 15.8]
68 (8.1)
[6.3, 10.1]
)
.1]
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 3.0]
0 (0.0)
[0.0, 0.4]
7.0)
, 46.3]
42 (34.4)
[26.1, 43.6]
39 (32.5)
[24.2, 41.7]
47 (39.2)
[30.4,48.5]
314 (37.3)
[34.1, 40.7]
7.0)
, 46.3]
44 (36.1)
[27.6, 45.3]
35 (29.2)
[21.2, 38.2]
47 (39.2)
[30.4, 48.5]
306 (36.4)
[33.1, 39.7]
1.8)
, 30.4]
28 (23.0)
[15.8, 31.4]
16 (13.3)
[7.8, 20.7]
30 (25.0)
[17.5, 33.7]
206 (24.5)
[21.6, 27.5]
1.2)
, 50.6]
48 (39.3)
[30.6, 48.6]
42 (35.0)
[26.5, 44.2]
55 (45.8)
[36.7, 55.2]
359 (42.7)
[39.3, 46.1]
)
12.8]
20 (16.4)
[10.3, 24.2]
10 (8.3)
[4.1, 14.8]
18 (15.0)
[9.1, 22.7]
102 (12.1)
[10.0, 14.5]
.2)
15.9]
14 (11.5)
[6.4, 18.5]
10 (8.3)
[4.1, 14.8]
11 (9.2)
[4.7, 15.8]
96 (11.4)
[9.3, 13.8]
)
.2]
8 (6.6)
[2.9, 12.5]
2 (1.7)
[0.2, 5.9]
2 (1.7)
[0.2, 5.9]
28 (3.3)
[2.2, 4.8]
e.
ys 0, 182, and 549.
 tocopherol-based-oil-in-water emulsion adjuvant containing 11.86 mg tocopherol
 tocopherol-based-oil-in-water emulsion adjuvant containing 11.86 mg tocopherol
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In this study, participants were primed with a single dose
f antigen-sparing (3.75 or 7.5 g of A/Indonesia/5/2005) AS03-
djuvanted vaccine 6 or 18 months before a single dose of
/turkey/Turkey/1/2005) vaccine, and the duration of heterolo-
ous antibody responses was measured out to 18 months following
ooster vaccination. Several important ﬁndings of relevance to
andemic planning were observed. Firstly, immune responses fol-
owing heterologous H5N1 booster vaccination 18 months after a
ingle priming dose were superior to the immune responses follow-
ng initial H5N1 vaccination. One prior study has shown a single
eterologous booster dose to be immunogenic, but this was fol-
owing a 90 g two-dose schedule. The response observed implies
hat an amnestic response occurred in the primed group, demon-
trating immunologic priming. Participants immunized with the
eterologous booster 6 months after the priming dose also had
ore robust immune responses than responses after the initial
5N1 vaccination. Superiority of the prime/boost regimen was  seen
n all adjuvant and antigen combinations tested. As reﬂected in
he SCR, heterologous boosting at 18 months was more effective
han at 6 months for the groups receiving 3.75 g HA with AS03B.
his ﬁnding was not noted in the groups receiving 7.5 g HA with
S03B. Finally, although quantiﬁcation of cellular immune assays
nd MN  tests are not standardized, it is notable that results from
hese tests generally corresponded with traditional measures of
accine immunogenicity.
The presence of baseline (Day 0) antibody to A/H5N1 strains in
dults, as measured by HI and MN,  has been observed in studies in
any parts of the world. In one European study of adults ≥61 years,
8% of participants had anti-inﬂuenza A/Vietnam/1194/2004-like
lade 1 strain HI antibody at baseline and 90% had MN  antibody[17].
n our study, MN  to A/Vietnam was high at baseline (Supplemen-
al Fig. 3), ranging from 83.1% to 96.7%, while baseline A/Indonesia
eropositivity ranged from 50.8% to 69.6%. Measurable antibody
gainst the Vietnam strain appears to be more common than for
he Turkey and Indonesia strains, which are closely related to
ach other, while the Vietnam strain is more distant. We  per-
ormed MN  testing against A/Vietnam, but not HI testing. The
eutralization assay is known to be more sensitive than HI to
dentify antibody levels in adults both before and following vac-
ination. This is postulated to be due to previous infection with
uman inﬂuenza viruses or immunization resulting in non-speciﬁc
ross-reactivity to H5N1 inﬂuenza due to cross-reactive epitopes
ommon to HA of different subtypes. The better sensitivity of the
N assay is thought to be due to its ability to detect a broader
ange of antibodies targeting a greater number of viral epitopes
18]. Similar to other studies of injected vaccines with emulsion-
ased adjuvants [32], injection site pain was the most common AE
bserved in this study, occurring in up to 78% of vaccine recipi-
nts compared with 8% of placebo recipients after the ﬁrst dose.
ain severe enough to limit normal activity (Grade 3) occurred
n less than 6% of vaccine participants overall at any of the three
accination time points. These AEs were short-lived in duration.
uscle aches and fatigue were the most frequently reported sys-
emic AEs, occurring in up to 35.1% of AS03-adjuvanted vaccine
ecipients, compared to 4.5–18.4% of those receiving placebo. Unso-
icited AEs were not different across groups. One SAE 10 days
fter H5N1, vaccination was considered by the local investigator
o be vaccine-related. The participant, a diabetic on varenicline
or smoking cessation, developed angina pectoris. Angina pec-
oris after vaccination with AS03-adjuvanted inﬂuenza vaccine has
ot previously been reported. While there is no clear evidence
f cardiovascular risk associated with varenicline [33], both dia-
etes and cigarette smoking increase the risk of cardiovascular
isease.
Since it is not known whether a strain with pandemic potential
ill develop the ability to efﬁciently spread among humans, it is 33 (2015) 559–567
desirable for pre-pandemic strain vaccines to produce long-lasting
priming allowing for effective booster vaccination. Drift-variant
priming response was clearly demonstrated in this population up to
18 months post-priming, and responses to a drifted strain persisted
for 6 and 18 months. The booster response occurred as early as 10
days post-vaccine, suggesting that rapid protection would occur in
primed persons. Beyond individual protection, this early booster
response may  favorably alter the dynamics of inﬂuenza transmis-
sion [34], and reduce the likelihood that variants of the pandemic
strain will emerge [35].
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